Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets (2017 - 2025)

Historic Assets for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.2 billion.

  • Crinetics Pharmaceuticals' Assets rose 2759.38% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2759.38%. This contributed to the annual value of $1.4 billion for FY2024, which is 12579.45% up from last year.
  • Crinetics Pharmaceuticals' Assets amounted to $1.2 billion in Q3 2025, which was up 2759.38% from $1.3 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Assets high stood at $1.4 billion for Q4 2024, and its period low was $163.5 million during Q1 2021.
  • Moreover, its 5-year median value for Assets was $421.7 million (2022), whereas its average is $655.2 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Assets plummeted by 3046.45% in 2023 and then soared by 21901.87% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Assets (Quarter) stood at $351.0 million in 2021, then rose by 0.33% to $352.2 million in 2022, then surged by 80.41% to $635.4 million in 2023, then soared by 125.79% to $1.4 billion in 2024, then fell by 16.63% to $1.2 billion in 2025.
  • Its Assets was $1.2 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.